When a rheumatologist prescribes Humira instead of a biosimilar, or an oncologist chooses Ocrevus over a generic alternative, itâs not because theyâre ignoring cost-itâs because theyâve seen what happens when patients switch. For specialists treating complex, life-altering conditions like multiple sclerosis, rheumatoid arthritis, or rare cancers, brand-name drugs arenât just preferred-theyâre often the only reliable option. And the numbers back this up: specialty drugs, which make up just 6.2% of all prescriptions, account for 71.1% of total U.S. prescription drug spending. Thatâs not a typo. One out of every $1.40 spent on meds goes to a drug used by less than 1 in 20 patients.
What Makes a Drug âSpecialtyâ?
Specialty drugs arenât just expensive. Theyâre defined by three things: high cost, complex use, and tight distribution. The Centers for Medicare & Medicaid Services (CMS) sets the bar at $670 per month, but more than half of these drugs cost over $100,000 a year. Many require injections or infusions, special refrigeration, or daily monitoring. Some, like Jakafi or Ofev, are used for conditions where thereâs literally no other treatment that works. A patient with pulmonary fibrosis doesnât get to try three different pills until one sticks-they need the right one, right away.
These arenât your run-of-the-mill statins or blood pressure pills. Theyâre biologics, gene therapies, or targeted cancer drugs developed over decades. Theyâre not mass-produced. Theyâre made in controlled environments, shipped in specialized coolers, and tracked from manufacturer to patient. Thatâs why only a handful of pharmacies are certified to handle them-and why switching isnât as simple as swapping a brand for a generic.
Why Specialists Donât Switch to Biosimilars or Generics
Youâd think with biosimilars available for drugs like Humira and Enbrel, doctors would jump at the cheaper option. But they donât. And hereâs why: patients arenât interchangeable.
A 2023 Medscape survey of 1,200 specialists found that 79% of rheumatologists and 82% of oncologists say prior authorization delays and formulary restrictions directly impact patient outcomes. One rheumatologist in Chicago told a patient who switched to a biosimilar that her joint pain returned within three weeks. She had to go back on Humira-and her insurance denied it. She ended up paying $850 a month out-of-pocket. Thatâs not rare. On the Medicare Rights Center forum, patients regularly share stories like hers: âMy doctor says biosimilars arenât appropriate for me,â they write. Not because theyâre being pushy, but because their condition is too unpredictable.
Studies show that up to 30% of branded drug dispensing is requested by prescribers or patients themselves. Thatâs not because theyâre being influenced by drug reps-itâs because theyâve seen the consequences of switching. A 2021 JAMA Network Open study found that when patients switched from brand to generic for specialty drugs, relapse rates increased in autoimmune conditions. No one wants to be the doctor who says, âItâs cheaper, but your disease might flare.â
The Financial Pressure Is Real-For Everyone
Itâs easy to blame drug companies for high prices. But the system is layered. The Federal Trade Commissionâs 2025 report revealed something startling: pharmacy benefit managers (PBMs) like CVS Caremark, Express Scripts, and OptumRx were marking up specialty generic drugs by thousands of percent. In some cases, they paid $10 for a vial and billed the insurer $1,200. Thatâs not the manufacturerâs doing-thatâs the middleman.
And itâs not just patients who suffer. Health systems are drowning. UnitedHealthcare reported that specialty drugs make up 53% of total pharmacy spend, even though theyâre only 3% of claims. Hospitals now have entire departments just to manage prior authorizations. Physicians spend an average of 13.4 hours a week on paperwork just to get one drug approved. Thatâs more time than most spend on patient education.
Patients arenât unaware of this. On Reddit, u/ChronicWarrior42 wrote: âI pay $1,200 a month for Ocrevus. My insurance covers 80%, but my deductible is $7,000. My specialist says there are no alternatives that work for my mutation. So I pay.â Thatâs not greed. Thatâs survival.
Why Generics Donât Work the Same Way Here
For a pill like Lipitor, a generic works because itâs chemically identical. But biologics? Theyâre made from living cells. Even if a biosimilar is approved as âsimilar,â small differences in manufacturing can change how the immune system responds. In autoimmune diseases, even a tiny shift can mean a flare-up, hospitalization, or permanent damage.
The FDA allows biosimilars, but doesnât require interchangeability studies for every condition. So a biosimilar approved for rheumatoid arthritis might not have been tested for psoriatic arthritis. A specialist wonât risk it. Theyâve seen patients lose mobility, vision, or lung function after switching. Thereâs no clinical trial that says, âItâs safe for everyone.â And in medicine, when evidence is thin, caution wins.
How the System Forces Prescribersâ Hands
Specialists donât choose brand drugs because theyâre paid to. The ProPublica analysis from 2016 found that doctors who received over $5,000 from drug companies prescribed brand-name drugs 50% more often. But hereâs the twist: even doctors who received nothing still preferred brands. Why? Because the system is stacked.
PBMs control formularies. They decide which drugs are covered and at what tier. Many plans put brand-name specialty drugs on Tier 3 or 4, while biosimilars are on Tier 2. Sounds fair-until you realize the patientâs out-of-pocket cost for the biosimilar is still $700 a month because of the way the PBM structures the copay. The brand? $50. Why? Because the manufacturer has a patient assistance program. The biosimilar? None.
So the doctor doesnât pick the brand because itâs more profitable. They pick it because itâs the only one the patient can actually afford to take.
Whatâs Changing-and Whatâs Not
The Inflation Reduction Act of 2022 let Medicare negotiate prices for some high-cost drugs. So far, itâs only targeted a handful, like insulin and a few cancer drugs. But experts say the next wave will hit specialty drugs hard. Drugs like Jakafi, Ofev, and Xtandi are likely targets in upcoming rounds. That could bring prices down-but only if manufacturers donât pull the drug from Medicare entirely.
Meanwhile, the FTC is pushing for transparency. Their 2025 report called PBM markups âa fundamental distortion.â Senator Bernie Sanders introduced the Specialty Drug Price Transparency Act in February 2025 to force PBMs to report their net prices. If passed, it could change how these drugs are priced.
But until then, specialists keep prescribing what works. Because for their patients, the stakes arenât about cost-theyâre about survival.
What Patients and Providers Need to Know
- Brand-name preference isnât about greed-itâs about risk. For many, switching means relapse.
- Generics and biosimilars arenât always interchangeable, especially in autoimmune or rare diseases.
- Prior authorization delays can cost weeks of treatment. One study found 42% of specialty drug starts are delayed by over a week.
- Financial assistance programs exist. The National Organization of Rare Disorders (NORD) helped 45,000 patients in 2023.
- Ask your provider: âIs there a patient assistance program for this drug?â Many donât know about them.
Why do specialists prescribe brand-name drugs even when generics are available?
Specialists prescribe brand-name drugs because many specialty conditions-like multiple sclerosis, rheumatoid arthritis, or rare cancers-have no proven alternatives. Biosimilars may be approved, but they havenât been tested in every patient subtype. A switch that works for one person might trigger a relapse in another. Doctors base decisions on real-world outcomes, not just price tags.
Are brand-name specialty drugs really that much more expensive than generics?
Yes-by orders of magnitude. A specialty brand can cost $38,000 per year per patient, while non-specialty drugs average $492. Even when a biosimilar exists, the out-of-pocket cost can be higher due to how insurance plans and pharmacy benefit managers (PBMs) structure copays. Some PBMs mark up generic specialty drugs by thousands of percent, making the âcheaperâ option more expensive for patients.
Do drug companies influence specialists to prescribe brand-name drugs?
Some do-ProPublica found doctors receiving over $5,000 from pharma companies prescribed brand-name drugs 50% more often. But many specialists prescribe brands even without payments. Their decision is based on clinical experience: patients who switched to biosimilars often had worse outcomes. The real driver isnât marketing-itâs fear of disease flare-ups and irreversible damage.
Can patients get help paying for specialty drugs?
Yes. Most brand-name manufacturers offer patient assistance programs that can reduce or eliminate out-of-pocket costs. Nonprofits like NORD helped 45,000 patients in 2023. But these programs are often hard to find. Patients need to ask their specialist or pharmacist: âIs there a patient support program for this drug?â Many donât know it exists.
Why do prior authorizations take so long for specialty drugs?
Specialty drugs require more documentation because theyâre expensive and often used for complex conditions. Insurers demand proof that less costly options have failed, that the patient meets strict criteria, and that the prescribing provider is qualified. The average physician spends 13.4 hours a week on prior authorizations-78% of that time is for specialty drugs. Delays of over a week are common, and for someone with a rapidly progressing disease, thatâs dangerous.
Prathamesh Ghodke
March 17, 2026 AT 05:28Stephen Habegger
March 18, 2026 AT 21:20Paul Ratliff
March 19, 2026 AT 21:51Andrew Muchmore
March 20, 2026 AT 09:49SNEHA GUPTA
March 20, 2026 AT 21:19Gaurav Kumar
March 22, 2026 AT 20:50David Robinson
March 24, 2026 AT 05:24Jeremy Van Veelen
March 25, 2026 AT 01:44Laura Gabel
March 25, 2026 AT 14:28jerome Reverdy
March 26, 2026 AT 13:26Andrew Mamone
March 28, 2026 AT 04:26Justin Archuletta
March 28, 2026 AT 20:28Sanjana Rajan
March 29, 2026 AT 23:26Kyle Young
March 30, 2026 AT 02:50Prathamesh Ghodke
March 30, 2026 AT 21:55